Theraclone Sciences, a US-based developer of therapeutic antibodies, backed by drugs group Amgen’s eponymous corporate venturing unit, has extended its series B round by $8m.
This is the second B-extension and the round now totals $50m. Return backers include Amgen Ventures and venture capital firms Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Versant Ventures and Zenyaku Kogyo.
Theraclone also secured $6m in venture debt from MidCap Financial and Silicon Valley Bank.
Theraclone, previously known as Spaltudaq Corp, was founded in 2004. Theraclone spun out of biotech investment and development company Accelerator Corp.